From Europe Biobank Week 2026 in Prague to Interphex Week Tokyo 2026, Haier Biomedical continuously strengthens global life sciences market presence through localized innovative products and profound ecosystem partnerships

QINGDAO, China, June 25, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, is making simultaneous presence at Europe Biobank Week 2026 in Prague, one of the most important conferences for the international biobanking community, and Interphex Week Tokyo 2026, Japan's largest pharma and biotech gathering.

To meet Europe's biobank needs and Japan's laboratory requirements for low-carbon, high-efficiency, and automated upgrades, Haier Biomedical launched multiple localized innovative products and solutions. With new product debuts, academic collaborations, and scenario-based innovations, Haier Biomedical presented to global markets its ability to combine localized technology innovation with deep, on-the-ground service.

Haier Biomedical advances globalization through localized R&D innovation and deep-rooted local service

Leveraging both major industry platforms, Haier Biomedical fully demonstrated its global scenario-based innovation capabilities, accelerating its shift from "product export" to "ecosystem integration." Localized R&D, localized product definition, and localized service capabilities are becoming the core drivers of overseas growth, translating the company's globalization strategy into sustainable growth results.

At Europe Biobank Week 2026, Haier Biomedical focused on automated, low-temperature storage solutions to enhance academic R&D and teaching practices, and to advance the development of biobanks in Europe.

The global launch of HAB80-60KA / HAB80-60KB automated ultra-low temperature sample storage system is a flexible, automated storage system designed to preserve sensitive biological samples at -80°C. It's ideal for applications ranging from 50,000 to over 200,000 samples, supports small molecule compound storage, core sample storage, and biorepositories including disease, population, and research biobanks. The system ensures end-to-end protection of sample temperature throughout the storage process.

Furthermore, it highlights low-carbon design, modular flexibility for scalable expansion, and AI-driven automated monitoring and management targeting European biobank needs. The "KA base + KB expansion" modular architecture enables on demand growth, and dual independent refrigeration for enhanced sample safety and long-term reliability.

It also features an intuitive real-time control and monitoring system that automatically records and updates sample status throughout the entire process from entry and inventory to dispatch. Users can monitor equipment operation anytime, anywhere, and easily locate samples to accelerate daily tasks and streamline inventory management.

At Europe Biobank Week 2026, Professor Marco Agostini from the Università degli Studi di Padova has brought his classroom to the Haier Biomedical booth, the collaboration is a deep integration of academia and Haier Biomedical ecosystem.

Meanwhile at Interphex Week Tokyo 2026, Haier Biomedical unveiled new products designed specifically to meet the Japanese market needs, including the narrow, slim DWL368BPST ultra-low temperature freezer developed for space-constrained Japanese laboratories with product definition and design optimized specifically for the needs of local Japanese laboratories.

The DWL368BPST features several key upgrades over conventional models. It is equipped with a dual independent refrigeration system that ensures sample safety even if one system fails, and a compact 670mm width specifically designed for space‑constrained Japanese laboratories. Performance improvements compared to conventional models include ±2°C temperature uniformity (vs. ±4°C), 26% lower energy consumption, 45% faster temperature recovery, and quieter operation below 44 dB.

Driven by scenario-based innovation, Haier Biomedical is advancing life science infrastructure toward smarter, more automated, and greener solutions. By deepening partnerships with universities, research institutions, biobanks, hospitals, and pharmaceutical companies, the company fosters an open ecosystem for scientific progress. Through long-term localized operations, Haier Biomedical has earned user trust globally, positioning itself as a reliable partner for sustainable growth in the life sciences industry.

https://www.haiermedical.com/

QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the front of a competitive global field and caps a three-phase international expansion that has delivered a compound annual growth rate exceeding 20 percent.

Euromonitor International is one of the world's leading independent market research firms, and its rankings are widely used as benchmarks across global procurement and industry analysis. The two No. 1 positions cover total global sales revenue and overseas sales revenue measured among Chinese-owned brands in the life science laboratory equipment category. The rankings span all global markets, confirming that Haier Biomedical is competing at the highest level against established international manufacturers.

The rankings also carry practical weight for international partners. In a field where equipment reliability, regulatory compliance, and long-term service support are critical to procurement decisions, independent verification of market leadership provides an additional layer of confidence for institutions evaluating suppliers.

Haier Biomedical's international growth began with targeted projects, working directly with organizations including UNICEF and the WHO to solve specific unmet needs and building a leading position in solar-powered vaccine storage. From there, the company scaled its distribution network to cover 160 countries through more than 800 active dealer relationships. The current phase focuses on embedding full operational capabilities in key regions: local warehousing, sales, marketing, product planning, and R&D.

The company now operates overseas R&D centers in the UK, Italy, and Japan, each focused on specific product lines including centrifuges, cold chain and automation storage solutions, incubators, and biosafety cabinets. In the UK and continental Europe, dedicated product specialists in automation and centrifuge technology provide on-site support for GMP compliance, air safety, and sample purification, positioning Haier Biomedical as a laboratory workflow partner. Service standards developed in the US and UK are being replicated across the EU, Southeast Asia, and South Asia.

In Q1 2026, revenue in Germany, Australia, and Canada grew more than 50 percent, while Eastern Europe, South Asia, and Brazil each exceeded 100 percent year-on-year growth, with centrifuges and incubators both doubling in volume. In the pharmaceutical sector, Haier Biomedical is part of the supply chains of multiple leading pharmaceutical companies across key countries including Switzerland, Germany, Denmark, Italy, Singapore, the US, Israel, and India. The company's Ultra Energy series holds all eight top positions in the US Energy Star rankings for its category, making it the bestselling line in that segment.

Looking ahead, Haier Biomedical is set to deepen its localization investments and expand its product range, with the goal of helping global biopharmaceutical and life sciences laboratories improve efficiency and sustainability, as part of the company's vision to lead the world in delivering integrated life sciences tools and intelligent productivity platforms.

For more information, visit https://www.haiermedical.com/.

Within its LIFE sustainability framework of Leadership, Integrity, Future, and Ecosystem, Haier Biomedical actively supports and implements all 17 United Nations Sustainable Development Goals (SDGs). Through continuous technological innovation and locally integrated strategies in global markets, the company empowers public health initiatives worldwide with key focuses of strengthening localized service networks, advancing cutting-edge scientific research, and driving sustainable development across industrial chains with innovative low-carbon solutions.

"In 2025, we achieved three strategic leaps: from products to scenarios, from China to the world, and from a single industry to a platform ecosystem. Guided by our philosophy of 'Intelligent of Life Science,' Haier Biomedical continues to deepen green, low‑carbon innovation and global health accessibility under our core 'LIFE' framework," said Tan Lixia, Chairwoman of Haier Biomedical.

Haier Biomedical remains committed to making R&D and innovation a strategic priority. It has established a clear three-tier R&D management structure that balances resource allocation, drives technological breakthroughs, and accelerates new product development. Guided by the dual engines of core technology advancement and deep user insight, the company ensures strategic alignment through mechanisms such as milestone reviews by the management committee, monthly progress reports, and weekly operational meetings. This approach has yielded strong results:

• R&D personnel account for 28.56% of the workforce, with total R&D investment reaching 323 million yuan (USD 47.25 million);
• New invention patents grew 50% year-on-year, and non-storage patents now represent 73% of the portfolio;
• It holds 428 software copyrights and has accumulated 51 provincial or higher-level science and technology awards, as well as involvement in setting 75 national, industry, group, and technical standards;
• Owns 34 technologies recognized as internationally leading and a track record of 0.70 patents and 0.18 software copyrights per million yuan in revenue.

Haier Biomedical is integrating AI into product R&D, launching "AI+" solutions that address key safety and efficient pain points in healthcare:

• The "AI+" Safety Cabinet, trained on over 7,000 annotated medicine vial images, achieves 99% recognition accuracy, covering 101 common vial types and significantly reducing medication errors.
• The Cytotoxic Drug Dispensing Robot with 3D-AI vision is developed for fully automated chemotherapy preparation, protecting healthcare workers from hazardous exposure.
• Its Fully Automated Cell Culture Workstation enables closed-loop cell processing from thawing to harvesting, improving standardization and traceability while reducing labor costs.

These innovations earned Haier Biomedical a second prize at the 2025 Qingdao Science and Technology Progress Award and first prize at the Shandong Provincial Science and Technology Progress Award.

In addition, Haier Biomedical has established a digitalized quality management process covering the entire journey from raw material intake to product dispatch, integrating digital capabilities into every aspect of production and quality control to drive smarter and more efficient quality management.

It has strengthened intelligent management and risk prevention through digitalization of the supply chain, quality and manufacturing. Its dual‑platform procurement system integrates supplier data and user feedback for real‑time quality optimization. Manufacturing digitalization enables full parameter monitoring, facial recognition for key processes, and real‑time SPC analytics. The digital quality platform makes quality visible, controllable, and assessable — reducing risks and ensuring product reliability.

Haier Biomedical's smart IoT factory adopts automation, digitalization, and intelligent connectivity to precisely control production and dynamically monitor quality, effectively reducing in-process quality risks. The company is also building intelligent medical factories that integrate equipment, data, and controls to establish a full lifecycle production management model.

Driven by its vision to be "Making Life Better," Haier Biomedical is dedicated to enhancing patient well‑being globally while making quality products accessible to more users. The company collaborates closely with international public welfare organizations, supporting communities through cash and product donations, totaling 1.406 million yuan (USD 205,697.8) during the reporting period.

Leveraging its technology and expertise, Haier Biomedical works with governments, NGOs, and universities to advance global health equity and make quality medical services more accessible. As a long‑term partner of GAVI, the company supports global immunization through its products. Since its inception in 2000, GAVI has served 1.2 billion children worldwide, significantly improving child health.

Haier Biomedical has made steady progress in its long‑term environmental investments, expanding its green product portfolio across energy saving, eco‑friendly materials, full lifecycle planning, and green packaging. The company has significantly reduced product energy consumption through innovations like Eco‑Drive technology and zero‑carbon solar direct‑drive cold storage.

During the reporting period, Haier Biomedical obtained 122 energy‑saving certificates covering 75 product models and added two new ENERGY STAR certified models, bringing the total to 34. The company has also partnered with institutions such as Eurofins, the University of Sheffield, and the University of Liverpool, providing low‑carbon equipment to support research while reducing environmental impact.

Furthermore, Haier Biomedical is committed to a diverse, equitable, and inclusive workplace and continuous talent development, with expanded dual career tracks for management and technical professionals. In late March 2026, following board and shareholder approval, the company established a compensation incentive fund to support equity incentives and employee stock ownership plans as part of its medium‑ to long‑term incentive programs.

Looking ahead, Haier Biomedical will continue its digital, global, and platform-driven transformation to build a world-leading integrated life science tools and intelligent productivity platform.

For more information, please visit: https://www.haiermedical.com/.

QINGDAO, China, April 30, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has officially published its 2025 annual report, posting full‑year revenue of 2.33 billion yuan (USD 340.77 million) with overseas revenue growing 17.9% year-on-year to 840 million yuan (USD 122.85 million), accounting for 36% of total revenue – a record high. Despite a complex global trade environment, Haier Biomedical delivered double‑digit growth across all international business sectors.

After a decade of global expansion, Haier Biomedical has evolved from "product export" to "brand globalization." In 2025, overseas revenue delivered strong compound growth, with double-digit increases across Europe, Asia-Pacific, the Americas, and Africa – including 26.0% growth in Asia-Pacific and 16.0% in Europe.

For the first time, the company unveiled its future strategic blueprint centered on "growth leapfrogging," driven by three pathways: market leap, industry leap, and model leap. The vision is to build a world-leading integrated life science tools and intelligent productivity platform.

Haier Biomedical continued to optimize its revenue structure in 2025, with new market sectors and overseas operations emerging as core engines of growth. New business segments such as smart medication, blood technology, laboratory solutions and more contributed 48.5% of total revenue, representing an 8.8% year-on-year increase.

Its ultra‑low and low‑temperature biomedical freezers ranked first in market share in six countries, such as Italy, while the company also led domestic peers in export volume of smart medication dispensing solutions.

Revenue from AI‑powered applications contributed 15% of total revenue, up 2.5 percentage points from 2024. It has built a multi‑layer AI infrastructure of "large models, AI agents, and AI terminals," developing 17 proprietary agents integrated into 13 automated solutions. AI‑powered automated pharmacies raised direct dispensing rates to 80% – 1.1x the industry average. Its fully automated cell workstation won the Ministry of Industry and Information Technology's top award for disruptive technology, and the fully closed automated cell expansion system has entered clinical trials to support bioartificial liver therapies.

In addition, Haier Biomedical's plasma separation system became the first Chinese solution to receive EU MDR certification. Its "Ultra Series" ultra-low temperature biomedical freezers have also achieved notable energy efficiency performance: the top 8 ranked products in the ENERGY STAR program are all from Haier Biomedical.

In 2025, the company's R&D investment reached 320 million yuan (USD 46.82 million), with new invention patents up 50% year‑on‑year to 1,620 patents. The on‑time product launch rate improved by 11%, and 11 solutions achieved industry‑first status. Haier Biomedical also became China's first to master stable 100,000‑rpm ultra‑high‑speed centrifugation technology, a breakthrough of a key technical bottleneck that continues to solidify its core competitiveness in the market.

To date, Haier Biomedical holds over 400 international product certifications and has partnered with nearly 80 international organizations, including WHO and UNICEF. Its distribution network spans more than 800 partners across over 160 countries and regions. Committed to a "one country, one strategy" approach, Haier Biomedical has established subsidiaries in four countries and localized operations in 18 more, combining rapid delivery with on‑the‑ground service to build deep global customer relationships.

Having reshaped its growth trajectory in 2025, Haier Biomedical also unveiled its three-year "543" strategic targets in the annual report:

• Deepen global penetration through localized operations with overseas revenue exceeding 50%;
• Accelerate strategic industry expansion through platform‑based external growth, with acquired businesses contributing no less than 40% of future revenue; 
• Drive future leadership through AI‑powered innovation, with AI‑related revenue accounting for over 30%.

Looking ahead, Haier Biomedical will leverage localized development, AI-driven innovation, and mergers and acquisitions as key catalysts to achieve a comprehensive leap in revenue structure, profit quality, and valuation fundamentals, advancing its goal of building a world‑leading integrated life science tools and intelligent productivity platform.

For more information, please visit https://www.haiermedical.com/.

At the summit, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the Company's global vision to achieve over 50% of global revenue from international markets by 2027 and over 50% revenue contribution beyond refrigeration by 2028. He emphasized that Europe remains a strategic priority within the company's globalization roadmap, which underscores the "In Europe, for Europe" localization principle of delivering products, services, and support tailored for regional regulatory standards, customer expectations, and application needs.

Outlining the 2026 European strategy, Semir Selimovic, director of North, Central & Eastern Europe of Haier Biomedical Europe, highlighted continued investment in local sales, service, and product expertise to strengthen responsiveness and execution across key markets. Europe has become one of Haier Biomedical's fastest-growing international regions, and this is supported by expanding local teams and a steadily broadening product portfolio.

Expanding from freezers to full solutions

Among the newly introduced products, the Plasma Apheresis System XJ-III drew particular attention. The system has obtained EU MDR certification, which marks a significant milestone in meeting Europe's stringent regulatory requirements and strengthens Haier Biomedical's position in blood and plasma technology. Across Europe, Haier Biomedical's CO₂ incubators, centrifuges, biosafety cabinets, and cold storage lines continue to gain market share, supported by energy-efficient technologies and compliance with regional certification standards. The product evolution presented in Rome demonstrates a move toward unlocking a full portfolio capable of supporting laboratories, hospitals, and life science institutions with end-to-end solutions.

Automation and intelligent blood management as growth engines

Daniele Pericolini, European Automation Solution Specialist of Haier Biomedical, outlined the Company's strategy to drive future growth through laboratory automation and intelligent blood management systems. Haier Biomedical's automated biobank solutions integrate RFID-enabled ultra-low temperature storage, modular automation platforms, and liquid nitrogen systems to enhance sample traceability and operational efficiency. By addressing challenges such as sample integrity, temperature tracking, and high-density storage, the Company has positioned itself within Europe's growing demand for advanced biobanking infrastructure.

Additionally, the U-Blood intelligent blood management system represents a shift from traditional cold storage to real-time connected blood supply chain management. Designed to reduce wastage, improve traceability, and support round-the-clock transfusion workflows, the solution aligns with Europe's increasing focus on safety, digitization, and zero-waste healthcare initiatives.

European customer recognition and brand alignment

The summit also featured success stories from four European partners representing Germany, Slovenia, France, and Denmark, which highlighted strong local validation of Haier Biomedical's solutions. In France, long-term partner showcased the jointly developed biosafety cabinet adapted to French standards, with over 230 units deployed across over 100 customers. In Denmark, Haier Biomedical partner shared its ultra-low temperature freezer success through public tenders and ongoing expansion into additional product categories. In Slovenia, large-scale pharmaceutical installations reinforced the Company's capabilities in managing complex, multi-unit projects. Partners from Central Europe also emphasized reliability, regulatory compliance, and after-sales support as key differentiators.

Strong international growth performance in 2025

Haier Biomedical's expanding European footprint is supported by a solid financial performance. In 2025, the Company reported revenue exceeding RMB 2.3 billion, with international revenue reaching RMB 840 million, which accounts for over 36% of total revenue and reflects continued global expansion.

Europe recorded double-digit growth, which contributed to a large portion of overall international revenue growth. The Company's AI-driven and automation-related solutions contributed approximately 15% of total revenue in 2025, which signalled accelerating technology-driven transformation. These results reflect a broader shift from hardware exports toward localized solution delivery supported by regional teams and certifications across over 18 countries.

As the European Partner Summit concluded, Haier Biomedical reaffirmed its commitment to strengthening localized operations, expanding automation and life science solutions, and advancing collaborative growth with partners. Through a combination of global innovation capabilities and local execution in Europe, the Company aims to further consolidate its position as a trusted life science solutions provider in 2026 and beyond.

For more information, please visit https://www.haiermedical.com/.